Giselle Romero Caimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giselle Romero Caimi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ezequiel Ridruejo
Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Ciudad Autónoma de Buenos Aires C1425ASG, Argentina
1 shared publication - Laura Alvarez
Laboratory of Biological Effects of Environmental Contaminants, Department of Human Biochemistry, School of Medicine, Ciudad Autónoma de Buenos Aires Universidad de Buenos Aires Buenos Aires Argentina
1 shared publication - Lucia Coli
Heidelberg University
1 shared publication - Noelia Victoria Miret
CONICET - Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas (INBIOMED), Laboratorio de Efectos Biológicos de Contaminantes Ambientales, Buenos Aires, Argentina
1 shared publication - Zahira Deza
Laboratory of Biological Effects of Environmental Contaminants, Department of Human Biochemistry, School of Medicine, Ciudad Autónoma de Buenos Aires Universidad de Buenos Aires Buenos Aires Argentina
1 shared publication
Latest Publications
- 28 December 2022
- Published by Wiley in Molecular Carcinogenesis
- Vol. 62 (3) , 398-407
Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF‐β1/pERK signaling pathway
Hepatocellular carcinoma (HCC) represents 90% of liver tumors. Statins may reduce HCC incidence. Its antitumor activities may be mediated by disrupting several hepatocarcinogenic pathways. To evaluate in vivo and in vitro the antiproliferative and antiangiogenic action of atorvastatin (AT) in the development of HCC as well as its mechanisms of action. In vivo model: hexachlorobenzene (HCB) was used to promote the development of HCC in Balb/C nude mice. Number of hepatic tumor, liver cell proliferation parameters (proliferating cell nuclear antigen, PCNA), angiogenesis, and VEGF levels were analyzed. In vitro model: Hep‐G2 and Ea‐hy926 cells were used to evaluate the effect of different doses of AT on HCB induced cell proliferation, migration, and vasculogenesis and to analyze proliferative parameters. In vivo: AT prevented liver growth and tumor development and inhibited PCNA, TGF‐β1, and pERK levels increase. AT prevented skin blood vessel formation. In vitro, AT prevented cell proliferation and migration as well as tubular formation in the endothelial cell line by inhibiting the MAPK ERK pathway. We were able to demonstrate the potential AT antiproliferative and antiangiogenic effects in an HCC model and the involvement of TGF‐β1 and pERK pathways.
- 28 December 2022
- Published by Wiley in Molecular Carcinogenesis
- Vol. 62 (3) , 398-407
Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF‐β1/pERK signaling pathway
Hepatocellular carcinoma (HCC) represents 90% of liver tumors. Statins may reduce HCC incidence. Its antitumor activities may be mediated by disrupting several hepatocarcinogenic pathways. To evaluate in vivo and in vitro the antiproliferative and antiangiogenic action of atorvastatin (AT) in the development of HCC as well as its mechanisms of action. In vivo model: hexachlorobenzene (HCB) was used to promote the development of HCC in Balb/C nude mice. Number of hepatic tumor, liver cell proliferation parameters (proliferating cell nuclear antigen, PCNA), angiogenesis, and VEGF levels were analyzed. In vitro model: Hep‐G2 and Ea‐hy926 cells were used to evaluate the effect of different doses of AT on HCB induced cell proliferation, migration, and vasculogenesis and to analyze proliferative parameters. In vivo: AT prevented liver growth and tumor development and inhibited PCNA, TGF‐β1, and pERK levels increase. AT prevented skin blood vessel formation. In vitro, AT prevented cell proliferation and migration as well as tubular formation in the endothelial cell line by inhibiting the MAPK ERK pathway. We were able to demonstrate the potential AT antiproliferative and antiangiogenic effects in an HCC model and the involvement of TGF‐β1 and pERK pathways.